IMR Press / EJGO / Volume 40 / Issue 3 / DOI: 10.12892/ejgo4500.2019
Open Access Original Research
Experimental study on the co-expression of double genes AdvCD40L-IRES2-ICOSL in mouse breast cancer model
T. Yang1,2,†H.-Z. Sun1,†Q.-Y. Guo3Q. Li1D.-S. Li1G. Bai1W. Wang1,*
Show Less
1 Jinan University, Guangzhou, Guangdong, China
2 Department of General Surgery, The First Affiliated Hospital, Jinzhou Medical University, Jinzhou, China
3 The Operating Room, The First Affiliaed Hospital, Jinzhou Medical University, Jinzhou, China

Contributed equally

Eur. J. Gynaecol. Oncol. 2019, 40(3), 389–393;
Published: 10 June 2019

Objective: This study aims to investigate the therapeutic effect of CD40L-IRES2-ICOSL adenoviral vector on mouse breast cancer model. Materials and Methods: CD40L, ICOSL, and CD40L-IRES2-ICOSL adenoviral vectors were constructed by gene transfection technique. Eighty BALB/c mice were selected, in which animal models of mouse breast cancer were established with the human MCF-7 breast cancer cell line. A total of 72 successful model in mice. Mice were randomly divided into four groups: control group, CD40L group, ICOSL group, and CD40L-IRES2-ICOSL group, with 18 mice in each group. Two weeks later, breast cancer cells transfected with empty vector and recombinant vectors were injected into the tumor body of mice. Histopathological changes, tumor volumes and changes in weight, and survival time of tumor bearing mice were observed. Results: The T infiltration of lymphocytes in tumors significantly increased in the CD40L, ICOSL, and CD40L-IRES2-ICOSL groups. Compared with the control group, tumor growth was retarded, volumes were reduced, and survival times were prolonged in tumor bearing mice in both the CD40L and ICOSL groups, and the differences between these two groups were statistically significant (p < 0.05). In particular, this difference was statistically significant in the CD40L-IRES2-ICOSL group (p < 0.01). However, there was no significant difference between the CD40L and ICOSL groups. Conclusions: In the treatment of the animal model of mice with breast cancer, the co-expression of double genes of Adv CD40L-IRES2-ICOSL can inhibit tumor growth and prolong the survival time of the MCF-7 human breast cancer bearing mice.

Breast cancer
Gene therapy
Figure 1.
Back to top